Compare QTRX & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTRX | ACB |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.0M | 164.8M |
| IPO Year | 2017 | 2016 |
| Metric | QTRX | ACB |
|---|---|---|
| Price | $3.47 | $2.77 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 466.3K | ★ 1.2M |
| Earning Date | 05-06-2026 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,632,000.00 | N/A |
| Revenue This Year | $25.49 | $6.31 |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 64.52 | N/A |
| 52 Week Low | $2.40 | $2.56 |
| 52 Week High | $8.77 | $6.67 |
| Indicator | QTRX | ACB |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 53.69 |
| Support Level | $3.30 | $2.73 |
| Resistance Level | $3.74 | $2.98 |
| Average True Range (ATR) | 0.28 | 0.08 |
| MACD | -0.08 | 0.04 |
| Stochastic Oscillator | 15.89 | 100.00 |
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.